New Mission, New Website coming soon! Learn more now.

Equities logo
Search
Close this search box.

Gilead Sciences Says Remdesivir Improved Clinical Recovery in COVID-19 Patients

Analysis of Gilead's late-stage study showed that 74.4% of remdesivir-treated patients recovered by day 14 versus 59.0% of patients receiving standard of care.

Image: Gilead Sciences workers with vials of remdesivir. Source: Gilead Sciences

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.

The company said the finding requires confirmation in prospective clinical trials.

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the study.

Findings from the analysis of its late-stage study showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.

Gilead shares were up nearly 2% at $76.14 in trading before the bell.

Reporting by Ankur Banerjee in Bengaluru; editing by Uttaresh.V and Anil D’Silva.

_____

Source: Reuters